Clinical trial endpoints: angiograms, events, and plaque instability

Area of Science:

• Cardiology
• Atherosclerosis Research
• Clinical Trials

Background:

• Coronary artery disease (CAD) risk assessment and intervention trials are crucial.
• Plaque rupture is a key event in atherothrombosis, leading to myocardial infarction (MI) and death.
• Large clinical trials for MI and death endpoints require significant resources and time.

Purpose of the Study:

• To evaluate the utility of surrogate endpoints in clinical trials for cardiovascular disease.
• To assess the impact of interventions on atherosclerotic lesion progression and regression.
• To understand the relationship between CAD progression and clinical cardiovascular events.

Main Methods:

• Utilizing clinical trials with surrogate endpoints focusing on atherosclerotic lesion progression/regression.
• Employing coronary angiography to visualize and measure changes in coronary artery lesions.
• Analyzing data from trials examining the effects of lipid-modifying therapy.

Main Results:

• Lipid-modifying therapy has consistently demonstrated a reduction in the progression of coronary artery disease.
• Surrogate endpoints allow for quicker clinical information acquisition with smaller patient cohorts.
• Atherosclerotic lesion progression correlates with clinical events like MI and coronary death.

Conclusions:

• Surrogate endpoints, such as lesion progression, offer a more efficient approach to evaluating cardiovascular interventions.
• Lipid-modifying therapies are effective in managing the underlying disease process of CAD.
• Targeting plaque rupture and thrombosis is a critical strategy for reducing cardiovascular morbidity and mortality.